BR112022021657A2 - Métodos de tratamento de crescimento celular anormal - Google Patents
Métodos de tratamento de crescimento celular anormalInfo
- Publication number
- BR112022021657A2 BR112022021657A2 BR112022021657A BR112022021657A BR112022021657A2 BR 112022021657 A2 BR112022021657 A2 BR 112022021657A2 BR 112022021657 A BR112022021657 A BR 112022021657A BR 112022021657 A BR112022021657 A BR 112022021657A BR 112022021657 A2 BR112022021657 A2 BR 112022021657A2
- Authority
- BR
- Brazil
- Prior art keywords
- kras
- cell growth
- abnormal cell
- treatment methods
- growth treatment
- Prior art date
Links
- 230000002159 abnormal effect Effects 0.000 title abstract 3
- 230000010261 cell growth Effects 0.000 title abstract 3
- 229940124647 MEK inhibitor Drugs 0.000 abstract 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 abstract 2
- 102100030708 GTPase KRas Human genes 0.000 abstract 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 abstract 1
- 206010069755 K-ras gene mutation Diseases 0.000 abstract 1
- 229940126685 KRAS G12R Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 102200006531 rs121913529 Human genes 0.000 abstract 1
- 102200006537 rs121913529 Human genes 0.000 abstract 1
- 102200006539 rs121913529 Human genes 0.000 abstract 1
- 102200006538 rs121913530 Human genes 0.000 abstract 1
- 102200006540 rs121913530 Human genes 0.000 abstract 1
- 102200006541 rs121913530 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063015883P | 2020-04-27 | 2020-04-27 | |
| PCT/US2021/029435 WO2021222278A1 (en) | 2020-04-27 | 2021-04-27 | Methods of treating abnormal cell growth |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022021657A2 true BR112022021657A2 (pt) | 2022-12-20 |
Family
ID=78332185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022021657A BR112022021657A2 (pt) | 2020-04-27 | 2021-04-27 | Métodos de tratamento de crescimento celular anormal |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230201198A1 (https=) |
| EP (1) | EP4142882A4 (https=) |
| JP (1) | JP2023523323A (https=) |
| KR (1) | KR20230011277A (https=) |
| CN (1) | CN115916346A (https=) |
| AU (1) | AU2021263742A1 (https=) |
| BR (1) | BR112022021657A2 (https=) |
| CA (1) | CA3175481A1 (https=) |
| IL (1) | IL297650A (https=) |
| MX (1) | MX2022013430A (https=) |
| WO (1) | WO2021222278A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7582694B2 (ja) | 2020-01-10 | 2024-11-13 | イミューニヤリング コーポレーション | Ｍｅｋ阻害剤及びその治療的使用 |
| TW202329967A (zh) * | 2022-01-21 | 2023-08-01 | 大陸商應世生物科技（南京）有限公司 | 治療腫瘤的藥物組合及用途 |
| EP4469086A4 (en) * | 2022-01-25 | 2026-01-21 | Verastem Inc | POLYTHERAPY FOR THE TREATMENT OF ABNORMAL CELL GROWTH |
| EP4488272A4 (en) * | 2022-02-28 | 2026-02-25 | Wigen Biomedicine Tech Shanghai Co Ltd | COMPOUND USED AS A FAK INHIBITOR AND ITS USE |
| CN118973580A (zh) * | 2022-04-08 | 2024-11-15 | 米拉蒂治疗股份有限公司 | 包含sos1抑制剂和mek抑制剂的组合疗法 |
| JP2025518795A (ja) * | 2022-06-03 | 2025-06-19 | ベラステム・インコーポレーテッド | 異常な細胞成長を処置するための併用療法 |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
| TW202517624A (zh) * | 2023-07-03 | 2025-05-01 | 美商醫療免疫工程公司 | Mek免疫腫瘤抑制劑醫藥組合物 |
| WO2025079712A1 (ja) * | 2023-10-12 | 2025-04-17 | 中外製薬株式会社 | ドライバー変異を有するがん患者における分子標的薬併用療法 |
| WO2025261499A1 (zh) * | 2024-06-20 | 2025-12-26 | 上海科州药物股份有限公司 | 蛋白激酶Mek抑制剂苯并噻唑的颗粒药物组合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2012DN01403A (https=) * | 2009-08-24 | 2015-06-05 | Genentech Inc | |
| CA2779843A1 (en) * | 2009-11-13 | 2011-05-19 | Infinity Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| US20130217710A1 (en) * | 2010-11-05 | 2013-08-22 | Glaxosmithkline Intellectual Property (No.2) Limited | Methods for treating cancer |
| US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| BR112017023821A2 (pt) * | 2015-05-06 | 2018-07-31 | Leidos Biomedical Res Inc | moduladores de k-ras |
| AU2018329925B2 (en) * | 2017-09-08 | 2025-05-29 | F. Hoffmann-La Roche Ag | Diagnostic and therapeutic methods for cancer |
| US11666574B2 (en) * | 2019-11-27 | 2023-06-06 | Turning Point Therapeutics, Inc. | Combination therapy involving diaryl macrocyclic compounds |
-
2021
- 2021-04-27 IL IL297650A patent/IL297650A/en unknown
- 2021-04-27 CN CN202180028579.0A patent/CN115916346A/zh active Pending
- 2021-04-27 MX MX2022013430A patent/MX2022013430A/es unknown
- 2021-04-27 CA CA3175481A patent/CA3175481A1/en active Pending
- 2021-04-27 KR KR1020227037020A patent/KR20230011277A/ko active Pending
- 2021-04-27 JP JP2022565600A patent/JP2023523323A/ja active Pending
- 2021-04-27 AU AU2021263742A patent/AU2021263742A1/en active Pending
- 2021-04-27 US US17/921,509 patent/US20230201198A1/en active Pending
- 2021-04-27 WO PCT/US2021/029435 patent/WO2021222278A1/en not_active Ceased
- 2021-04-27 EP EP21797285.0A patent/EP4142882A4/en active Pending
- 2021-04-27 BR BR112022021657A patent/BR112022021657A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021263742A1 (en) | 2022-09-22 |
| CN115916346A (zh) | 2023-04-04 |
| EP4142882A4 (en) | 2024-06-05 |
| CA3175481A1 (en) | 2021-11-04 |
| EP4142882A1 (en) | 2023-03-08 |
| KR20230011277A (ko) | 2023-01-20 |
| WO2021222278A1 (en) | 2021-11-04 |
| IL297650A (en) | 2022-12-01 |
| MX2022013430A (es) | 2022-11-14 |
| US20230201198A1 (en) | 2023-06-29 |
| JP2023523323A (ja) | 2023-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022021657A2 (pt) | Métodos de tratamento de crescimento celular anormal | |
| MX2023007084A (es) | Inhibidores de pan-kras de azaquinazolina. | |
| Marshak et al. | Prognostic factors for local control of early glottic cancer: the Rabin Medical Center retrospective study on 207 patients | |
| Hershman et al. | The effects of pronator quadratus repair on outcomes after volar plating of distal radius fractures | |
| Hill et al. | Infectious complications associated with the use of acellular dermal matrix in implant-based bilateral breast reconstruction | |
| Coakley et al. | Postoperative antibiotics correlate with worse outcomes after appendectomy for nonperforated appendicitis | |
| Quesnel et al. | Third-generation bisphosphonates for treatment of sensorineural hearing loss in otosclerosis | |
| Molena et al. | Incidence and risk factors for respiratory complications in patients undergoing esophagectomy for malignancy: a NSQIP analysis | |
| BR112015012731A2 (pt) | uso de eribulina no tratamento de câncer de mama | |
| Harati et al. | Soft tissue sarcomas of the distal lower extremities: A single-institutional analysis of the prognostic significance of surgical margins in 120 patients | |
| Van Gompel et al. | Acoustic neuroma observation associated with an increase in symptomatic tinnitus: results of the 2007–2008 Acoustic Neuroma Association survey | |
| Li et al. | Treatment and predictive factors in patients with recurrent laryngeal carcinoma: A retrospective study | |
| Crombie et al. | Health-related quality of life of patients treated with primary chemoradiotherapy for oral cavity squamous cell carcinoma: a comparison with surgery | |
| Ribeiro et al. | Modified radical mastectomy: a pilot clinical trial comparing the use of conventional electric scalpel and harmonic scalpel | |
| Manola et al. | The effectiveness of sternocleidomastoid flap versus superficial musculoaponeurotic system flap for the prevention of Frey syndrome and facial depressed deformity in parotid surgery for pleomorphic adenoma | |
| Hay et al. | Outcomes of salvage surgery for the oropharynx and larynx: a contemporary experience in a UK Cancer Centre | |
| Canonico et al. | Thyroid surgery in the elderly: a comparative experience of 400 patients from an Italian university hospital | |
| Al-Salool et al. | Emotional distress in head-and-neck cancer patients scheduled for chemoradiation or radiotherapy alone | |
| Michelotti et al. | Should surgeons use arm restraints after cleft surgery? | |
| Telmesani et al. | Telmesani radiological classification of the location of the vertical segment of the facial nerve: impact on surgical approach in cochlear implant surgery | |
| Ogreden et al. | Comparison of Frey syndrome rates following superficial parotidectomy and partial superficial parotidectomy for pleomorphic adenoma | |
| Nguyen et al. | Influence of smoking status on treatment outcomes after post-operative radiation therapy for non-small-cell lung cancer | |
| Yeh et al. | EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid | |
| Wang et al. | Time to treatment in patients with stage iii non–small cell lung cancer | |
| Price et al. | Effect of Descemet membrane endothelial keratoplasty on color vision in patients with Fuchs dystrophy |